Condition: Solid Tumor, Adult · Sponsor: Hutchmed
This is a first-in-human (FIH), multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A830 in participants with histologically or cytologically confirmed, unresectable, advanced, or metastatic solid tumors\*, who are refractory or progressed on/after available standard treatment. The study will be conducted in 2 parts: Dose Escalation (Part A, Phase I), approximately 57 participants will be enrolled. Dose Optimization (Part B, Phase IIa), approximately 90 participants will be enrolled.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | — |
| Hunan Cancer Hospital | Changsha, China | — |
| West China Hospital of Sichuan University | Chengdu, China | — |
| The Sixth Affiliated Hospital,Sun Yat-sen University | Guangzhou, China | — |
| Shandong Cancer Hospital | Jinan, China | — |
| Jiangsu Province Hospital | Nanjing, China | — |
| Shanxi Provincial Cancer Hospitial | Taiyuan, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07718581